Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation

Bristol Myers Squibb highlighted two ongoing AI collaborations aimed at closing lung cancer care gaps, in a corporate-responsibility release distributed via ACCESS Newswire. A multi-year, first-phase collaboration with Microsoft uses FDA-cleared AI algorithms on Microsoft's Precision Imaging Network to flag hard-to-detect lung nodules and track follow-up care, recruiting rural hospitals and community clinics as pilot sites. Through a collaboration with Tempus AI, BMS deployed the Tempus Next Pathways program across 13 community health systems, raising guideline-directed biomarker testing rates from 73% to 84% at participating sites.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.